SCHEMBL4293684

SCHEMBL4293684

O=c1cc(O)ccn1C1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 1/20 0.59
SLC28A2 O43868 1/20 0.59
SLC29A1 Q99808 1/20 0.59
SLC28A3 Q9HAS3 1/20 0.59
LMNA P02545 2/20 0.56
MTOR P42345 2/20 0.56
THRB P10828 1/20 0.56
MDM2 Q00987 1/20 0.56
NCOA1 Q15788 1/20 0.56
NCOA3 Q9Y6Q9 1/20 0.56
MAPT P10636 1/20 0.53
CDA P32320 1/20 0.53
SLC5A2 P31639 2/20 0.48
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
BLM P54132 2/20 0.47
GMNN O75496 1/20 0.47
TP53 P04637 1/20 0.47
NFKB1 P19838 1/20 0.47
DNMT1 P26358 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352974 1.00 SLC28A1 (0.59) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL12594002 1.00 SLC28A1 (0.59) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL9293560 1.00 SLC28A1 (0.59) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL13657982 1.00 SLC28A1 (0.59) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL2115033 0.84 LMNA (0.62) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL21184966 0.84 LMNA (0.62) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL6676522 0.84 LMNA (0.62) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL16179302 0.80 SLC28A1 (0.59) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL7028245 0.79 MAPT (0.63) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL7028251 0.79 MAPT (0.63) SLC28A1SLC28A2SLC29A1SLC28A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258843-A1 Compositions Containing Antiviral Compounds and Methods of Using the Same MALLINCKRODT INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258843-A1 Compositions Containing Antiviral Compounds and Methods of Using the Same EIF2AK2, MAVS, IRF3 SLC28A1 80/4885SLC28A2 191/4885SLC29A1 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.